Table 2

OC use among adenocarcinoma cases, squamous cell carcinoma cases, and community controls: Adjusted ORs and 95% CIs

ControlsAdenocarcinomasSquamous cell carcinomas
nanaORbORc (95% CI)naORbORc (95% CI)
Never used OCs76231.0d1.0d341.0d1.0d
Ever used OCs2311011.61.0 (0.5–1.9)1051.10.8 (0.4–1.5)
 Former use187701.30.9 (0.5–1.7)851.10.9 (0.5–1.7)
 Current usee41283.0f1.8 (0.7–4.3)191.30.8 (0.3–2.0)
Duration of use
 2 years or less70271.40.9 (0.4–2.0)331.20.8 (0.4–1.7)
 2–6 years81281.20.7 (0.3–1.5)331.00.7 (0.4–1.5)
 >6 years77432.1f1.2 (0.6–2.6)381.20.9 (0.4–2.0)
P (trend) = 0.58P (trend) = 0.88
Age at first OC use
 Before 1758292.2f1.0 (0.5–2.3)311.50.9 (0.4–2.1)
 18 or 1956251.81.1 (0.5–2.4)321.61.2 (0.5–2.6)
 20–2258261.71.0 (0.4–2.2)261.20.8 (0.4–1.8)
 After 2256181.20.9 (0.4–1.9)150.70.6 (0.2–1.3)
P (trend) = 0.69P (trend) = 0.22
Years since first use
 10 or fewer59252.01.3 (0.5–3.2)211.10.7 (0.3–1.9)
 10–1539192.11.0 (0.4–2.6)322.4f1.8 (0.7–4.4)
 15–2050211.71.2 (0.5–2.9)201.11.0 (0.4–2.4)
 >2080331.30.7 (0.3–1.6)310.90.6 (0.3–1.3)
P (trend) = 0.52P (trend) = 0.36
Years since last use
 2 or fewer59312.6f1.3 (0.5–3.1)311.40.9 (0.4–2.1)
 2–1059211.60.8 (0.4–2.0)261.10.7 (0.3–1.6)
 10–1865321.81.2 (0.6–2.5)250.90.8 (0.4–1.8)
 >1845141.00.6 (0.2–1.5)221.20.9 (0.4–2.0)
P (trend) = 0.46P (trend) = 0.63
  • a Excludes missing responses.

  • b Adjusted for age (<30, 30–39, 40–49, 50–59, and ≥60 years) and ethnicity (Caucasian versus non-Caucasian).

  • c Adjusted for age, ethnicity, income (<$30,000, $30,000–$50,000, and >$50,000), HPV (negative or low-risk; types 16, 18, 18-related, or other cancer-associated types; unknown), lifetime number of sexual partners (<4 versus ≥4), and number of Pap smears in last 10 years (<10 versus ≥10).

  • d Referent group for the column.

  • e Defined as OC use 12 months before diagnosis for cases and at reference date for controls.

  • f 95% CI excludes 1.0.